@MattNachtrab The notion that Barry is blacked out from buying shares on the open market until p3 data is released is unlikely unless he is privy to material company information not yet publicly disclosed. Also, one successful investment in Sarepta is not indicative that SAVA will be.
@MattNachtrab @anyones2cents Not everything is a conspiracy. Sometimes events unfold simply due to incompetence, or taking things for granted, or lack of execution, or luck, or all of the above.
@MattNachtrab Your point about the NIH grants is puzzling. SAVA received 3.9, .9, and 0 dollars for the years ‘21, ‘22, and ‘23 respectively. Those reimbursement amounts are a fraction of the cost to run just one p3 trial let alone two. Even if the shorts caused the NIH grants to dry up, so.
@MattNachtrab That figure seems a tad high based on their financials. But even if that is the case, SAVA only needs to reach the point in time when data is released on the first p3 trial. SAVA has more than enough cash to pay for patients to stay on simufilam after the 52 week extension ends.
@MattNachtrab@doj I do not understand. You tweeted a long marketing pitch how based on patients, data, etc… that simufilam would be approved by the fda. You should be buying shares with the stock taking a 50% haircut unless you don’t believe what you wrote just yesterday
@wildace@optionsgeneral@thetradingchick Terrible example. Bezos had a vision of e-commerce and more importantly executed on that vision. They had real first mover advantage and no one was a close second. DM is one of many, lacks execution & if it disappeared tomorrow, it would barely cause a blip in the AM market.
@InvestorVillage your website has been down for 5 days yet you have chosen to not communicate with your customers as to the issue and timing of return of service. If you are closing down the website then have some courtesy by letting your paying customers know. Business 101.
@YOLO19761@ThomasUBarton1 Barton is not looking for push back on twitter only praise. When you are as wrong on investments as he has been whether $plxp, $ziop, $ride, $brcn, $eols, $pgen, $muds, etc… praise is in short supply. He is quick with excuses and will never admit he was wrong.
@ThomasUBarton1 I must have gotten under this Barton guy’s thin skin as he banned me for suggesting $plxp ‘s paid promotion was not a great indication of how consumers felt about vazalore. Someone appears a bit too emotional and biased about his investment.
@ThomasUBarton1 Every review except for a few on vazalore from your cvs link was from a paid promotion 3-4 months ago. The reviews on amazon are more indicative of how some people feel about vazalore including some price feedback. Feels like it is going to be a slow and long ramp. $plxp
@pharmamaven are you the same guy some people call robbie the car guy on Investor Village? Are you the poster, RobCos, who has had some of the worst stock recommendations in $xon, $ziop, $crmd, $bsgm, etc…?
@ZIOPHARMFAN Awww big daddy, Bayer, is so scared!!!! Lol. I suggest you immediately short shares on Monday in anticipation of the BBB coming down hard on Plx and their advertising.
@FelixHartkorn Sorry Felix but that is not quite right. The S8 was simply a registration statement of the shares that can potentially sold at some future date by those individuals listed. The number of shares listed in that S8 have not been sold and did not result in any additional shares